Logo image of URGN

UROGEN PHARMA LTD (URGN) Stock Fundamental Analysis

NASDAQ:URGN - Nasdaq - IL0011407140 - Common Stock - Currency: USD

14.87  +1.63 (+12.31%)

After market: 14.9 +0.03 (+0.2%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to URGN. URGN was compared to 557 industry peers in the Biotechnology industry. Both the profitability and financial health of URGN have multiple concerns. URGN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year URGN has reported negative net income.
In the past year URGN has reported a negative cash flow from operations.
URGN had negative earnings in each of the past 5 years.
URGN had a negative operating cash flow in each of the past 5 years.
URGN Yearly Net Income VS EBIT VS OCF VS FCFURGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of URGN (-55.91%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -55.91%
ROE N/A
ROIC N/A
ROA(3y)-60.9%
ROA(5y)-76.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
URGN Yearly ROA, ROE, ROICURGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K

1.3 Margins

Looking at the Gross Margin, with a value of 89.68%, URGN belongs to the top of the industry, outperforming 92.28% of the companies in the same industry.
In the last couple of years the Gross Margin of URGN has declined.
URGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.33%
GM growth 5Y-2.05%
URGN Yearly Profit, Operating, Gross MarginsURGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K -400K -500K

More info and screens

3

2. Health

2.1 Basic Checks

URGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, URGN has more shares outstanding
The number of shares outstanding for URGN has been increased compared to 5 years ago.
URGN has a better debt/assets ratio than last year.
URGN Yearly Shares OutstandingURGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
URGN Yearly Total Debt VS Total AssetsURGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -3.68, we must say that URGN is in the distress zone and has some risk of bankruptcy.
URGN has a Altman-Z score (-3.68) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.68
ROIC/WACCN/A
WACC8.41%
URGN Yearly LT Debt VS Equity VS FCFURGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

2.3 Liquidity

A Current Ratio of 5.65 indicates that URGN has no problem at all paying its short term obligations.
URGN has a Current ratio (5.65) which is in line with its industry peers.
URGN has a Quick Ratio of 5.47. This indicates that URGN is financially healthy and has no problem in meeting its short term obligations.
URGN has a Quick ratio of 5.47. This is comparable to the rest of the industry: URGN outperforms 57.81% of its industry peers.
Industry RankSector Rank
Current Ratio 5.65
Quick Ratio 5.47
URGN Yearly Current Assets VS Current LiabilitesURGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

6

3. Growth

3.1 Past

URGN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.47%.
URGN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.98%.
Measured over the past years, URGN shows a very strong growth in Revenue. The Revenue has been growing by 438.30% on average per year.
EPS 1Y (TTM)6.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.15%
Revenue 1Y (TTM)8.98%
Revenue growth 3Y23.46%
Revenue growth 5Y438.3%
Sales Q2Q%7.84%

3.2 Future

URGN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.30% yearly.
The Revenue is expected to grow by 49.35% on average over the next years. This is a very strong growth
EPS Next Y6.8%
EPS Next 2Y32.41%
EPS Next 3Y32.89%
EPS Next 5Y25.3%
Revenue Next Year26.62%
Revenue Next 2Y60.23%
Revenue Next 3Y53.02%
Revenue Next 5Y49.35%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
URGN Yearly Revenue VS EstimatesURGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
URGN Yearly EPS VS EstimatesURGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for URGN. In the last year negative earnings were reported.
Also next year URGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
URGN Price Earnings VS Forward Price EarningsURGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
URGN Per share dataURGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as URGN's earnings are expected to grow with 32.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.41%
EPS Next 3Y32.89%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for URGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UROGEN PHARMA LTD

NASDAQ:URGN (6/18/2025, 8:00:01 PM)

After market: 14.9 +0.03 (+0.2%)

14.87

+1.63 (+12.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners97.25%
Inst Owner Change15.91%
Ins Owners2.1%
Ins Owner Change0.68%
Market Cap685.66M
Analysts82.86
Price Target28.43 (91.19%)
Short Float %9.05%
Short Ratio1.28
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-10.84%
Min EPS beat(2)-12.75%
Max EPS beat(2)-8.93%
EPS beat(4)1
Avg EPS beat(4)1.28%
Min EPS beat(4)-12.75%
Max EPS beat(4)34.01%
EPS beat(8)3
Avg EPS beat(8)2.97%
EPS beat(12)6
Avg EPS beat(12)2.48%
EPS beat(16)7
Avg EPS beat(16)1.72%
Revenue beat(2)0
Avg Revenue beat(2)-9.49%
Min Revenue beat(2)-12.92%
Max Revenue beat(2)-6.05%
Revenue beat(4)1
Avg Revenue beat(4)-6.87%
Min Revenue beat(4)-12.92%
Max Revenue beat(4)2.09%
Revenue beat(8)4
Avg Revenue beat(8)-4.26%
Revenue beat(12)4
Avg Revenue beat(12)-5.62%
Revenue beat(16)5
Avg Revenue beat(16)-6.41%
PT rev (1m)-14.56%
PT rev (3m)-24.08%
EPS NQ rev (1m)-0.31%
EPS NQ rev (3m)-2.03%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.21%
Revenue NQ rev (1m)-1.03%
Revenue NQ rev (3m)-8.37%
Revenue NY rev (1m)-3.74%
Revenue NY rev (3m)-9.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.46
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.18
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)-2.33
FCFYN/A
OCF(TTM)-2.32
OCFYN/A
SpS1.99
BVpS-1.01
TBVpS-1.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -55.91%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.68%
FCFM N/A
ROA(3y)-60.9%
ROA(5y)-76.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.33%
GM growth 5Y-2.05%
F-Score2
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 48.22%
Cap/Sales 0.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.65
Quick Ratio 5.47
Altman-Z -3.68
F-Score2
WACC8.41%
ROIC/WACCN/A
Cap/Depr(3y)47.01%
Cap/Depr(5y)104.37%
Cap/Sales(3y)0.32%
Cap/Sales(5y)2.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.15%
EPS Next Y6.8%
EPS Next 2Y32.41%
EPS Next 3Y32.89%
EPS Next 5Y25.3%
Revenue 1Y (TTM)8.98%
Revenue growth 3Y23.46%
Revenue growth 5Y438.3%
Sales Q2Q%7.84%
Revenue Next Year26.62%
Revenue Next 2Y60.23%
Revenue Next 3Y53.02%
Revenue Next 5Y49.35%
EBIT growth 1Y-55.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.62%
EBIT Next 3Y46.36%
EBIT Next 5YN/A
FCF growth 1Y-19.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.79%
OCF growth 3YN/A
OCF growth 5YN/A